 |
PDBsum entry 2kem
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Extended structure of citidine deaminase domain of apobec3g
|
|
Structure:
|
 |
DNA dc->du-editing enzyme apobec-3g. Chain: a. Fragment: unp residues 191-284. Synonym: apobec-related cytidine deaminase, arcd, apobec-related protein, arp-9, cem-15, cem15. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: apobec3g. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
NMR struc:
|
 |
10 models
|
 |
|
Authors:
|
 |
E.Harjes,P.J.Gross,K.Chen,Y.Lu,K.Shindo,R.Nowarski,J.D.Gross, M.Kotler,R.S.Harris,H.Matsuo
|
Key ref:
|
 |
E.Harjes
et al.
(2009).
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model.
J Mol Biol,
389,
819-832.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
30-Jan-09
|
Release date:
|
02-Jun-09
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q9HC16
(ABC3G_HUMAN) -
DNA dC->dU-editing enzyme APOBEC-3G from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
384 a.a.
194 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
*
PDB and UniProt seqs differ
at 5 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.5.4.38
- single-stranded Dna cytosine deaminase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 2'-deoxycytidine in single-stranded DNA + H2O + H+ = a 2'-deoxyuridine in single-stranded DNA + NH4+
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
389:819-832
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model.
|
|
E.Harjes,
P.J.Gross,
K.M.Chen,
Y.Lu,
K.Shindo,
R.Nowarski,
J.D.Gross,
M.Kotler,
R.S.Harris,
H.Matsuo.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Human APOBEC3G (A3G) belongs to a family of polynucleotide cytidine deaminases.
This family includes APOBEC1 and AID, which edit APOB mRNA and antibody gene
DNA, respectively. A3G deaminates cytidines to uridines in single-strand DNA and
inhibits the replication of human immunodeficiency virus-1, other retroviruses,
and retrotransposons. Although the mechanism of A3G-catalyzed DNA deamination
has been investigated genetically and biochemically, atomic details are just
starting to emerge. Here, we compare the DNA cytidine deaminase activities and
NMR structures of two A3G catalytic domain constructs. The longer A3G191-384
protein is considerably more active than the shorter A3G198-384 variant. The
longer structure has an alpha1-helix (residues 201-206) that was not apparent in
the shorter protein, and it contributes to catalytic activity through
interactions with hydrophobic core structures (beta1, beta3, alpha5, and
alpha6). Both A3G catalytic domain solution structures have a discontinuous
beta2 region that is clearly different from the continuous beta2 strand of
another family member, APOBEC2. In addition, the longer A3G191-384 structure
revealed part of the N-terminal pseudo-catalytic domain, including the
interdomain linker and some of the last alpha-helix. These structured residues
(residues 191-196) enabled a novel full-length A3G model by providing physical
overlap between the N-terminal pseudo-catalytic domain and the new C-terminal
catalytic domain structure. Contrary to predictions, this structurally
constrained model suggested that the two domains are tethered by structured
residues and that the N- and C-terminal beta2 regions are too distant from each
other to participate in this interaction.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Fig. 4. A structural comparison A3G191-384-2K3A (PDB ID code
2kem; this study), A3G193-384 (PDB ID code 2kbo^20), A3G197-380
(PDB ID code 3e1u^22), and A2 (PDB ID code 2nyt^23). (a–d)
α-carbon-traced ribbon schematics for the aforementioned
structures. The β2 regions are highlighted by blue ovals and
shown in green in (b)–(d). The interdomain linker region in
(a) is indicated by an arrow. (e–h) Polypeptide backbone and
chemical contact schematics for the β2 and β1 regions of
A3G191-384-2K3A, A3G193-384, A3G197-380, and A2, respectively.
Amino acid positions are numbered and, if the residue is
conserved, shown in red. In (e) and (f), observed NOEs are
indicated by arrows. In (g) and (h), predicted hydrogen bonds
are indicated by broken lines, and labels correspond to
distances between the amide nitrogen and the carbonyl oxygen
atoms.
|
 |
Figure 7.
Fig. 7. HIV restriction activity of A3G-2K3A. (a) A histogram
reporting the infectivity of Vif-deficient HIV-1 produced in the
presence of a GFP control expression vector, wild-type A3G-GFP,
or full-length A3G-2K3A-GFP. (b) Representative immunoblots of
virus particles and cellular lysates A3G, CA and Tubulin were
detected using anti-GFP, anti-p24 and anti-tubulin antibodies,
respectively.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2009,
389,
819-832)
copyright 2009.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
L.S.Shlyakhtenko,
A.Y.Lushnikov,
M.Li,
L.Lackey,
R.S.Harris,
and
Y.L.Lyubchenko
(2011).
Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G.
|
| |
J Biol Chem,
286,
3387-3395.
|
 |
|
|
|
|
 |
D.Lavens,
F.Peelman,
J.Van der Heyden,
I.Uyttendaele,
D.Catteeuw,
A.Verhee,
B.Van Schoubroeck,
J.Kurth,
S.Hallenberger,
R.Clayton,
and
J.Tavernier
(2010).
Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.
|
| |
Nucleic Acids Res,
38,
1902-1912.
|
 |
|
|
|
|
 |
F.Autore,
J.R.Bergeron,
M.H.Malim,
F.Fraternali,
and
H.Huthoff
(2010).
Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations.
|
| |
PLoS One,
5,
e11515.
|
 |
|
|
|
|
 |
J.S.Albin,
and
R.S.Harris
(2010).
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
|
| |
Expert Rev Mol Med,
12,
e4.
|
 |
|
|
|
|
 |
M.A.Carpenter,
E.Rajagurubandara,
P.Wijesinghe,
and
A.S.Bhagwat
(2010).
Determinants of sequence-specificity within human AID and APOBEC3G.
|
| |
DNA Repair (Amst),
9,
579-587.
|
 |
|
|
|
|
 |
S.Wissing,
N.L.Galloway,
and
W.C.Greene
(2010).
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.
|
| |
Mol Aspects Med,
31,
383-397.
|
 |
|
|
|
|
 |
J.D.Salter,
J.Krucinska,
J.Raina,
H.C.Smith,
and
J.E.Wedekind
(2009).
A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function.
|
| |
Biochemistry,
48,
10685-10687.
|
 |
|
|
|
|
 |
J.L.Smith,
W.Bu,
R.C.Burdick,
and
V.K.Pathak
(2009).
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
|
| |
Trends Pharmacol Sci,
30,
638-646.
|
 |
|
|
|
|
 |
K.Strebel,
J.Luban,
and
K.T.Jeang
(2009).
Human cellular restriction factors that target HIV-1 replication.
|
| |
BMC Med,
7,
48.
|
 |
|
|
|
|
 |
L.Chelico,
P.Pham,
J.Petruska,
and
M.F.Goodman
(2009).
Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G.
|
| |
J Biol Chem,
284,
27761-27765.
|
 |
|
|
|
|
 |
Y.Iwatani,
D.S.Chan,
L.Liu,
H.Yoshii,
J.Shibata,
N.Yamamoto,
J.G.Levin,
A.M.Gronenborn,
and
W.Sugiura
(2009).
HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
|
| |
Proc Natl Acad Sci U S A,
106,
19539-19544.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |